Navigation Links
BioMed Realty Trust Reports Third Quarter 2007 Financial Results
Date:11/7/2007

SAN DIEGO, Nov. 7 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment trust focused on providing real estate to the life science industry, today announced financial results for the third quarter ended September 30, 2007.

Highlights:

-- Funds from operations (FFO) for the quarter were $30.8 million, or

$0.45 per diluted share

-- Net income available to common stockholders increased 13% to

$12.2 million versus the third quarter of 2006

-- Total assets of $3.0 billion at quarter end represented a 40.6%

increase from September 30, 2006

-- Executed 16 leasing transactions representing greater than 290,000

square feet, bringing the year-to-date total gross leasing transaction

volume to 741,000 square feet:

-- Thirteen new leases totaling approximately 146,000 square feet,

bringing the year-to-date 2007 total for new leases to

approximately 288,000 square feet, and

-- Three leases amended to extend their terms and totaling

approximately 144,000 square feet, bringing the year-to-date 2007

total for amendments, extensions and renewals to approximately

453,000 square feet

-- Increased the occupancy rate of our operating portfolio to 93.3%

-- Commenced construction on an approximately 280,000 square foot Class A

laboratory/office facility in East Cambridge, Massachusetts, owned by

our joint venture with Prudential Real Estate Investors

-- Closed on the acquisition of two properties located in our core markets

for total consideration of $49.0 million, bringing the 2007

ket leases, net 6,339 7,551

Deferred leasing costs, net 119,699 129,322

Deferred loan costs, net 17,052 17,608

Prepaid expenses 4,608 3,627

Other assets 31,959 16,039

Total assets $3,008,162 $2,692,642

LIABILITIES AND STOCKHOLDERS' EQUITY

Mortgage notes payable, net $397,341 $403,836

Secured construction loan 389,904 286,355

Secured term loan 250,000 250,000

Exchangeable senior notes 175,000 175,000

Unsecured line of credit 216,847 228,165

Security deposits 7,513 7,704

Dividends and distributions payable 25,557 19,847

Accounts payable, accrued expenses, and other

liabilities 81,195 62,602

Acquired below-market leases, net 25,220 25,101

Total liabilities 1,568,577 1,458,610

Minority interests 19,269 19,319

Stockholders' equity:

Preferred stock, $.01 par value, 15,000,000

shares authorized: 7.375% Series A cumulative

redeemable preferred stock, $230,000,000

liquidation preference ($25.00 per share),

9,200,000 shares issued and outstanding at

September 30, 2007 222,413 -

Common stock, $.01 par value, 100,000,000

shares authorized, 65,465,839 and 65,425,598

shares issued and outstanding at September

30, 2007 and December 31, 2006, respectively 655 654

Additional paid-in capital 1,275,347 1,272,243

Accumulated other comprehensive income 6,945 8,417

Dividends in excess of earnings (85,044) (66,601)

Total stockholders' equity 1,420,316 1,214,713

Total liabilities and stockholders' equity $3,008,162 $2,692,642

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except share and per share data)

(Unaudited)

For the Three Months For the Nine Months

Ended September 30, Ended September 30,

2007 2006 2007 2006

Revenues:

Rental $49,382 $49,197 $146,351 $115,808

Tenant recoveries 15,084 14,632 47,264 39,870

Other income 366 9 8,445 79

Total revenues 64,832 63,838 202,060 155,757

Expenses:

Rental operations 12,789 11,030 38,784 30,030

Real estate taxes 5,079 5,682 16,538 14,409

Depreciation and amortization 17,665 18,481 54,556 46,283

General and administrative 5,283 4,609 15,990 13,162

Total expenses 40,816 39,802 125,868 103,884

Income from operations 24,016 24,036 76,192 51,873

Equity in net (loss)/income

of unconsolidated

partnerships (261) 20 (694) 62

Interest income 239 218 809 813

Interest expense (7,043) (13,346) (21,013) (30,383)

Income from continuing

operations before

minority interests 16,951 10,928 55,294 22,365

Minority interests in

continuing operations of

consolidated partnerships 51 15 (61) 115

Minority interests in continuing

operations of operating

partnership (545) (497) (1,821) (1,131)

Income from continuing

operations 16,457 10,446 53,412 21,349

Income from discontinued

operations before gain on sale

of assets and minority interests - 383 639 1,156

(Loss)/gain on sale of real

estate assets (1) - 1,087 -

Minority interests attributable

to discontinued operations - (17) (74) (61)

(Loss)/income from

discontinued operations (1) 366 1,652 1,095

Net income 16,456 10,812 55,064 22,444

Preferred stock dividends (4,241) - (12,628) -

Net income available to

common stockholders $12,215 $10,812 $42,436 $22,444

Income from continuing operations

per share available to common

stockholders:

Basic and diluted earnings per

share $0.19 $0.17 $0.62 $0.40

Net income per share available to

common stockholders:

Basic and diluted earnings per

share $0.19 $0.18 $0.65 $0.42

Weighted-average common shares

outstanding:

Basic 65,308,702 60,477,672 65,300,802 52,822,498

Diluted 68,274,908 63,646,647 68,262,086 55,926,343

BIOMED REALTY TRUST, INC.

FUNDS FROM OPERATIONS(In thousands, except share and per share data)

(Unaudited)

The following table provides the calculation of our FFO and a reconciliation to net income available to common stockholders (in thousands, except per share amounts):

For the Three Months For the Nine Months

Ended September 30, Ended September 30,

2007 2006 2007 2006

Net income available to common

stockholders $12,215 $10,812 $42,436 $22,444

Adjustments:

Minority interests in operating

partnership 545 514 1,895 1,192

Loss/(gain) on sale of real estate

assets 1 - (1,087) -

Depreciation and amortization -

real estate assets

(unconsolidated partnerships) 366 20 745 60

Depreciation and amortization -

real estate assets (consolidated

entities-discontinued operations) - 137 228 411

Depreciation and amortization -

real estate assets (consolidated

entities-continuing operations) 17,665 18,481 54,556 46,283

Funds from operations $30,792 $29,964 $98,773 $70,390

Funds from operations per share -

diluted $0.45 $0.47 $1.45 $1.26

Weighted-average common shares

outstanding - diluted 68,274,908 63,646,647 68,262,086 55,926,343

We present funds from operations, or FFO, because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides an operating performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.

year-to-date total acquisitions to $653.8 million:

-- 238,000 square feet of industrial/warehouse space located in South

San Francisco, California, which is currently fully leased and

targeted for future redevelopment as laboratory/office space

-- 67,000 square feet of laboratory/office space located in San

Diego, California, which is fully leased to Artes Medical, Inc.

-- Disposed of two non-core assets, previously held for sale and owned by

our joint venture with Prudential Real Estate Investors

-- Amended our $250 million secured term loan, extending the term to

August 2012, lowering the borrowing rate by 60 basis points, and, when

combined with our in-place interest rate swap, fixing the effective

interest rate at 5.8% into 2010

-- Amended our unsecured line of credit, increasing the available

borrowings to $600 million, reducing the borrowing rate, extending the

term to August 2011 and increasing the accordion feature to

$1.0 billion

"We are very pleased to once again report a strong quarter of financial performance. Our leasing team continues to execute across our core markets, including leasing activity in San Diego, San Francisco, Seattle, Pennsylvania and New York. We remain optimistic as we see continued strength in the life science industry and improving occupancy rates in our core markets," commented Alan D. Gold, President and Chief Executive Officer of BioMed Realty Trust.

"Our development and redevelopment programs continue to make strong progress, and we are excited to have now commenced construction on the new 280,000 square foot Class A laboratory and office facility in East Cambridge that we own with our partner Prudential Real Estate Investors," added Mr. Gold.

Third Quarter 2007 Financial Results

Total revenues for the quarter increased to $64.8 million from $63.8 million in the third quarter of 2006, due primarily to the addition of properties through acquisitions, partially offset by a reduction in revenues from properties generating revenues in 2006 which are currently undergoing redevelopment. Net income available to common stockholders for the quarter was $12.2 million, or $0.19 per diluted share, compared to $10.8 million, or $0.18 per diluted share, in the third quarter of 2006.

FFO during the quarter increased 2.7% to $30.8 million from $30.0 million in the comparable period in 2006. FFO per diluted share was $0.45 for the third quarter of 2007 versus $0.47 in the third quarter of 2006.

FFO is a supplemental non-GAAP financial measure used in the real estate industry to measure and compare the operating performance of real estate companies. A complete reconciliation containing adjustments from GAAP net income available to common stockholders to FFO and a definition of FFO are included at the end of this release.

Financing Activity

On August 1, 2007, the company amended its $250 million secured term loan facility and $500 million unsecured revolving line of credit, reducing the borrowing rates under the facilities and increasing the available borrowings under the revolving facility from $500 million to $600 million. The borrowing rate under the secured term loan was reduced by 60 basis points, which, when combined with the interest rate swap agreement previously entered into by the company, provides an effective interest rate of 5.81% for the facility until the swap expires in 2010. The amendment also extends the term of the secured facility to August 1, 2012 and provides greater flexibility with respect to covenants.

In addition to increasing the available borrowings to $600 million, the amendment to the unsecured line of credit extends the term to August 1, 2011, reduces the borrowing rate and provides greater flexibility with respect to covenants. BioMed may extend the maturity date of the revolving credit facility to August 1, 2012 and may increase the amount of the facility to $1.0 billion upon satisfying certain conditions.

During the third quarter, the company also entered into four new interest rate swaps that have the effect of fixing the LIBOR portions of interest rates on $535 million of its variable rate debt. Two of the interest rate swaps with an aggregate notional amount of $150 million fix LIBOR at 4.68% through August 2011. The remaining two interest rate swaps with an aggregate notional amount of $385 million fix LIBOR at 4.82% through September 2008.

As of September 30, 2007, the company's consolidated debt included fixed-rate mortgage indebtedness with an aggregate outstanding principal amount of $385.8 million, excluding $11.5 million of debt premium, and a weighted-average effective interest rate of 5.43% at quarter-end; the $250 million secured term loan; $175 million aggregate principal amount of 4.50% exchangeable senior notes due 2026; $216.8 million in outstanding borrowings under the company's $600 million unsecured revolving line of credit, with a weighted-average effective interest rate of 6.72% at quarter-end; and $389.9 million in outstanding borrowings under the company's $550 million acquisition and construction loan secured by the Center for Life Science | Boston property, with a weighted-average effective interest rate of 6.38% at quarter-end. The company's debt to total capitalization ratio was 43.1% at September 30, 2007.

"Our strong financial results for the quarter continue to strengthen our credit profile. We are pleased to celebrate another series of successful financing transactions, which were completed in a very difficult global credit market environment, and we appreciate the continued support of our lenders," commented Kent Griffin, Chief Financial Officer of BioMed Realty Trust. "We are fortunate to have a strong liquidity position, with ample capital capacity to continue to execute our business plan, particularly the funding of our development and redevelopment pipeline. In addition, through the use of interest rate swaps that have the effect of fixing interest rates at historically favorable levels, we have significantly mitigated our near-to-medium term exposure to interest rate risk."

Portfolio Update

During the quarter, the company acquired the following two properties:

-- Pacific Center Boulevard -- two office/laboratory buildings comprising

approximately 67,000 square feet in the Sorrento Valley submarket of

San Diego, California that are now fully leased to Artes Medical, Inc.

-- Forbes Boulevard -- one building comprising approximately 238,000

square feet in the South San Francisco submarket of San Francisco,

California that is fully leased and targeted for future redevelopment

as laboratory/office space

The company, through its joint venture with Prudential Real Estate Investors, disposed of certain non-core assets during the quarter, including 25,000 square feet of retail space and additional developable pad sites in Cambridge, Massachusetts and a laboratory/office building and surrounding land parcels in New Haven, Connecticut.

As of September 30, 2007, BioMed Realty Trust owned or had interests in 103 buildings, located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. The company's portfolio was comprised of the following, with its operating portfolio 93.3% leased to 111 tenants, as of September 30, 2007:

Rentable

Square Feet

Operating portfolio 6,626,723

Repositioning and redevelopment properties 1,871,353

Construction in progress 1,941,000

Land parcels 1,293,000

Total proforma portfolio 11,732,076

Quarterly Distributions

BioMed Realty Trust's board of directors previously declared a third quarter 2007 dividend of $0.31 per share of common stock, and a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from July 16, 2007 through October 15, 2007.

Earnings Guidance

Based on results for the first nine months of 2007, the company has increased earnings guidance for the year ending December 31, 2007. The company's revised 2007 guidance for net income per diluted share and FFO per diluted share is set forth and reconciled below.

2007

(Low - High)

Projected net income per diluted share available to

common stockholders $0.79 - 0.81

Add:

Minority interest $0.04

Real estate depreciation and amortization $1.06

Projected FFO per diluted share $1.89 - 1.91

The results for the first nine months of 2007 include approximately $7.7 million, or $0.11 per diluted share, of lease termination income earned in the first and second quarters of 2007.

The company's initial 2008 guidance for net income per diluted share and FFO per diluted share is set forth and reconciled below.

2008

(Low - High)

Projected net income per diluted share available to

common stockholders $0.67 - 0.77

Add:

Minority interest $0.03

Real estate depreciation and amortization $1.16

Projected FFO per diluted share $1.86 - 1.96

Consistent with the 2007 guidance, the company's 2008 guidance does not include the impact of future acquisition activities. In addition, the company's 2008 guidance does not include any expected lease termination income.

The foregoing estimates are forward-looking and reflect management's view of current and future market conditions, including certain assumptions with respect to leasing activity, rental rates, occupancy levels, interest rates, and the amount and timing of development and redevelopment activities. The company's actual results may differ materially from these estimates.

Supplemental Information

Supplemental operating and financial data are available in the Investor Relations section of the company's web site at http://www.biomedrealty.com.

Teleconference and Web Cast

BioMed Realty Trust will conduct a conference call and audio web cast at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) Thursday, November 8, 2007 to discuss the company's financial results and operations for the quarter. The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at http://www.biomedrealty.com and http://www.earnings.com, or live by calling (866) 770-7125 (domestic) or (617) 213-8066 (international) with call ID number 10729297. The call will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 3:00 p.m. Pacific Time on Thursday, November 8, 2007 through midnight Pacific Time on Tuesday, November 13, 2007 by calling (888) 286-8010 (domestic) or (617) 801-6888 (international) and using access code 99167797.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 68 properties, representing 103 buildings with approximately 8.5 million rentable square feet, as well as approximately 1.9 million square feet of development in progress. These properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

BIOMED REALTY TRUST, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

September 30, December 31,

2007 2006

(Unaudited)

ASSETS

Investments in real estate, net $2,742,603 $2,457,538

Investment in unconsolidated partnerships 21,741 2,436

Cash and cash equivalents 18,424 25,664

Restricted cash 10,003 6,426

Accounts receivable 3,722 5,985

Accrued straight-line rents, net 32,012 20,446

Acquired above-mar
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
2. Biomedtex Inc. Announces A. Marc Rocca as President and CEO
3. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
4. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
5. BioMed Realty Trust to Report 2007 Third Quarter Results
6. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
7. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
8. Universal Health Realty Income Trust Announces Dividend
9. Healthcare Realty Trust Announces Public Offering of Common Stock
10. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
11. AUDIO from Medialink and Allergan: Women Not Sure Who to Trust on Anti-Aging Skin Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest ... . , Millions of individuals in the United States and Canada wear eyeglasses. Once ... to both correct vision and make a fashion statement. Even celebrities use glasses as ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: